GH: Shield now covers 80% of eligible patients, driving rapid commercial and clinical expansion
Q2 saw strong revenue and volume growth, with Shield expanding coverage to 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are driving clinical adoption, while Shield’s commercial momentum and multi-cancer detection features set it apart.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.